FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
September 24, 2013
TORONTO, ONTARIO – CardioComm Solutions, Inc. (CardioComm Solutions) (TSX VENTURE: EKG) confirms that a recent interview with the Wall Street Analyst (WSA) will be featured on the front page of www.thewallstreetanalysts.com for two business days. The interview with Etienne Grima, the Company’s Chief Executive Officer, will be made available to their global investor audience which includes fund managers, analysts, investment bankers, individual investors, and members of the financial press.
“The purpose of this interview was to provide an overview of the impact of the Company’s recent news developments, to provide the investment community a viewpoint on opportunities and challenges in the health monitoring market sector and to describe how CardioComm Solutions is being positioned to capitalize on those opportunities. The interview also gave us an opportunity to overview our products and services, both current and planned, and to provide a glimpse of our future growth strategies,” stated Mr. Simi Grosman, member of the Board of Directors for the Company.
“This interview allowed us to review the 17 months since our initial HeartCheckTM PEN product clearance and to provide a window on new opportunities and new product and technology lines that we see coming. The +40 year old consumer with risk factors for atrial fibrillation (AF) and stroke is our primary consumer target market. During 2013 we have worked to broaden use of the HeartCheckTM and SMART Monitoring technologies as easy to use and cost effective solutions for large scale and individual screening efforts as a means to find AF and to prevent stroke. We are now also targeting pharmacists and health fitness providers as an important channel to help expand ECG screening through a HeartCheckTM ECG Screening Partner Program which will allow for access to those individuals currently under prescription therapies as well as those interested in preserving their health,” said Etienne Grima, Chief Executive Officer for CardioComm Solutions. “Finally, the interview also provided an opportunity to confirm that we are actively engaged in developing new medical ECG management software solutions, an example of which will meet the needs of the US-based mobile cardiac telemetry market.”
The WSA is a multi-media financial research and publishing company reporting to the investment community on publicly held companies. They service a large following of private and institutional investors that look for promising small and micro cap opportunities, accessing an investment community across markets and continents using print, web, audio, streaming video, email alerts, electronic and syndicated news story distribution, Investment conferences, and Chartered Financial Analyst (CFA) analyst coverage.
About CardioComm Solutions
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.